compared to 1.2% in non‐Indigeneous ALL patients genotyped at INCA22; (ii) TPMT*3A haplotype ranges in frequency from 0.6% in Yanomami to 18.8% of Paiter‐Surui from the Brazilian Amazon,31 compared to 2.1% in the non‐Indigenous ALL patients.22 This evidence concerns the gene TPMT and acute lymphoblastic leukemia.